Valens™ AH Vaccine Adjuvants for Human Health
A family of high-performance aluminium hydroxide adjuvants designed for human vaccines.
One platform. Four grades. Engineered for quality, flexibility, and scalable supply.
The Valens™ AH range is a family of high-performance aluminium hydroxide adjuvants developed for human vaccines. Each grade features a positively charged surface that enables efficient adsorption of negatively charged antigen, supporting the induction of robust humoral immune responses. Valens™ AH adjuvants can also be combined with other immunostimulatory components to activate additional immune pathways.
Available in a range of aluminium oxide concentrations, the Valens™ AH portfolio provides formulation flexibility to accommodate diverse vaccine development needs. Backed by consistent product quality and scalable manufacturing, the platform supports programs from early-stage research through commercial production.
Products in the range
- Valens™ AH 1.5
- Valens™ AH 2.0
- Valens™ AH 2.0 HA (coming soon!)
- Valens™ AH 3.0
Why Choose Valens™ AH?
Efficient Antigen Adsorption
Positive surface charge supports strong negatively charged antigen binding
Enhanced Humoral Immune Responses
Well-established aluminium hydroxide adjuvant technology for human vaccines.
Formulation Flexibility
Available in multiple concentrations to meet diverse development needs.
High Purity & Low Bioburden
Manufactured to high quality standards and sterilized by irradiation.
Exceptional Quality & Consistency
Produced under cGMP guidelines and manufactured in accordance with Ph. Eur. requirements.
Reliable Global Supply
Backed by SPI Pharma's established global manufacturing and supply network
| Characteristic | Valens™ AH 2.0 HA | Valens™ AH 2.0 | Valens™ AH 3.0 | Valens™ AH 1.5 |
| Assay Al₂O₃ % | 1.9–2.1% | 1.9–2.1% | 2.9–3.1% | 1.4–1.6% |
| Protein Absorption* | 3.5–4.0 | 2.5 | 2.5 | 2.5 |
| Particle Size | 5 µm | 25 µm | 25 µm | 25 µm |
| Product Status | Coming Soon! | Available | Available | Available |
*(Adsorption Capacity) mg BSA (Bovine Serum Albumen) adsorbed / mg of Al
Performance you can count on
The Valens™ AH family builds on decades of experience in vaccine adjuvant technologies. Across the portfolio, customers benefit from:
- Well-stablished aluminium hydroxide adjuvant technology
- Scalable manufacturing capabilities
- Technical expertise from development through commercialization
The SPI Pharma Advantage
20+ Years of Vaccine Adjuvant Expertise
SPI Pharma's experience, together with strategic industry partnerships, supports vaccine developers with trusted adjuvant solutions and a growing pipeline of innovative technologies.
Quality You Can Trust
Manufactured to stringent quality standards with a focus on consistency and reliability.
Secure Global Supply
Scalable manufacturing and reliable supply to support programs from clinical development through commercial production.
Download Our Resources
Ready to accelerate your vaccine development?
Let’s bring your innovation to market faster.